© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Merck’s investigational antiretroviral is a reverse transcriptase¬ translocation inhibitor.
Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
Antibodies protect monkeys against SHIV.
Gene editing in monkeys creates SHIV-resistant immune cells.
Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.
Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.
Scientists succeeded in editing the animals’ stem cells to resist an HIV-like virus and ultimately shrink their viral reservoir.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
Researchers added more power to the vaccine that showed modest protection against humans in Thailand in 2009.
Recent scientific findings have spawned a renewed commitment to conducting biomedical research on primates.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
